To read the full article sign up for free or sign in.

Mundipharma to commercialize Samsung Bioepis’ biosimilars in Taiwan and Hong Kong

Jan. 14, 2020

HONG KONG – Global pharmaceutical company Mundipharma Pte Ltd. is gaining exclusive commercialization rights in Taiwan and Hong Kong to four biosimilar candidates from South Korean biopharma Samsung Bioepis Co. Ltd. targeting immunology and oncology.

BioWorld Asia Deals and M&A

Free access to BioWorld coronavirus articles

BioWorld

The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...

Today's news in brief

BioWorld

BioWorld briefs for Jan. 27, 2023.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 27, 2022.

Biogen, Eisai win FDA clearance for AD therapy Leqembi

BioWorld

As expected, the U.S. FDA gave its go-ahead to lecanemab, an amyloid-beta binder for mild cognitive impairment caused by Alzheimer’s disease (AD) and mild AD –...

J.P. Morgan Healthcare Conference: ‘Bright’ year ahead for cell, gene therapies, says ARM

BioWorld

After long years of painstaking work, the commercialization of cell and gene therapies picked up pace in 2022, with multiple approvals. More progress is expected...

Upgrade your daily dose of biopharma and medtech news

Mundipharma to commercialize Samsung Bioepis’ biosimilars in Taiwan and Hong Kong